Symposium in Conjunction With the 15th St Gallen
International Breast Cancer Conference
This activity is provided
by prIME Oncology.
CLOSING IN ON THE END GAME
FOR HER2+ BREAST CANCER
THURSDAY
16 March 2017
12.45 –13.45
HALL ABC
Austria Center Vienna
Bruno-Kreisky-Platz 1
Vienna, Austria
This educational activity is supported
by Puma Biotechnology.
CLOSING IN ON THE END GAME
FOR HER2+ BREAST CANCER
Thursday, 16 March 2017
12.45 – 13.45
Hall ABC
Austria Center Vienna
Chair
Wolfgang Janni, MD, PhD
University of Ulm
Ulm, Germany
Faculty
José Baselga, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Javier Cortés, MD, PhD
Ramón y Cajal University Hospital
Madrid, Spain
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology.
This activity provides content that is evidencebased, balanced, and free of commercial bias, with
a primary objective to improve competence and
performance of learners in order to improve patient care.
Sunshine Act and EFPIA Disclosure Code
prIME Oncology complies with all Sunshine Act
reporting requirements as outlined by CMS and
applicable manufacturers and with EFPIA Disclosure
Code reporting requirements.
Agenda
Welcome and introduction
Wolfgang Janni, MD, PhD
12.45 Effective management of HER2-positive breast
cancer: Do you know the rules of the game?
Wolfgang Janni, MD, PhD
12.50 Thoughts from a grand master: Biological
insights into improved HER2 targeting
José Baselga, MD, PhD
13.05 Closing in on that winning move: Optimizing
adjuvant HER2-targeted therapy
Javier Cortés, MD, PhD
13.25 Supporting the players: Minimizing side
effects and maintaining quality of life
Wolfgang Janni, MD, PhD
13.35 Interactive panel discussion
Faculty Panel
13.45 prIME Points™
Wolfgang Janni, MD, PhD
Adjourn
Register online: www.prIMEoncology.org/breast-vienna-2017